BETHESDA, Md., April 19 (UPI) -- U.S. scientists have created a simple modification in an anti-cancer treatment currently in clinical trials that greatly improves the drug's effectiveness.
The improvement by Enzon Pharmaceuticals Inc.'s David Filpula and colleagues at the National Cancer Institute is said to also reduce side effects in experiments with laboratory mice.
The research centers on an immunotoxin called SS1P that targets and destroys cells producing the surface protein mesothelin.
Ovarian, pancreatic and malignant mesothelioma cells all produce abnormally large amounts of mesothelin and, therefore, are targets for SS1P.
FULL STORY :--- via UPI
